Nuevocor is an IND-stage biotech developing novel therapies for genetic cardiomyopathies driven by aberrant mechanobiology using its proprietary PrOSIATM platform. Its lead candidate, NVC-001, is a first-in-class AAV-based gene therapy designed to reduce forces to the nucleus and restore nuclear envelope integrity in LMNA-related dilated cardiomyopathy (LMNA DCM). NVC-001 has shown dramatic survival benefits in preclinical models, high transduction levels, and a clean safety profile in GLP toxicology studies and large animal models. The company plans a first-in-human, open-label, multicenter, ascending single-dose Phase 1/2 trial in early 2026 with sites across the U.S. and Europe and will run a concurrent natural history study. Proceeds from the financing will support the Phase 1/2 trial through clinical proof-of-concept and the company will establish an office in Paris to support clinical development. Nuevocor positions its approach to treat shared disease pathways across multiple cardiomyopathies rather than individual gene replacement, targeting indications not amenable to traditional gene replacement therapy. Nuevocor is a Singapore-headquartered, preclinical-stage biotech company working in gene therapy. The article does not provide product- or pipeline-level details. According to ACRA filings accessed by DealStreetAsia (DATA VANTAGE), the company has raised an additional $11.6 million in funding. The filings indicate the capital came from existing investors but do not name them. The report does not disclose the funding instrument, use of proceeds, operating metrics, past rounds, founding year, or specific future plans. Nuevocor is a preclinical-stage biopharmaceutical company focused on developing adeno-associated virus (AAV) gene therapies for genetically defined cardiac diseases with high unmet need. Its lead program targets lamin A/C dilated cardiomyopathy (LMNA DCM) and is built on decades of research by its scientific co-founders. The company leverages novel technologies from co-founders at A*STAR and gene therapy and cardiac disease modelling expertise from collaborators at Stanford and the National University of Singapore. Led by founding CEO Dr Yann Chong Tan, Nuevocor aims to advance its lead AAV-based program through preclinical development. The company also plans to use its target discovery platform to address other untreatable cardiomyopathies. Nuevocor closed a $24M Series A to support these efforts.

Total raised

$81M

Funding rounds

3

Latest round

Series B

Latest activity

May 2025